In addition to the venture funds, Burrill & Company has a dedicated private equity team focused on investing in undervalued small/midcap public companies and selected buy-outs and spin-outs from pharma, biotech, and other life sciences entities. This group leverages Burrill & Company’s deep industry experience and broad network to actively manage holdings and create value through working with management. Investment decisions come from proprietary deal flow created by the diverse business units within Burrill & Company, and these deals are not typically available to generalist managers.